rhIL-11治疗急性髓系白血病化疗后血小板减少的疗效评价

目的观察并评估急性髓系白血病(AML)化疗后血小板减少患者应用重组人白细胞介素11(rhIL-11)的疗效和不良反应。方法将45例急性髓系白血病化疗后血小板减少患者随机分为实验组及对照组,实验组在化疗后24h开始使用rhIL-11,按30μg/(kg d)的剂量皮下注射,直至血小板恢复至≥100×109/L后停用,对照组在化疗后则不用rhIL-11治疗。结果实验组与对照组化疗前血小板计数差异无统计学意义(P>0.05),化疗后实验组的血小板计数明显高于对照组(P<0.05),低血小板持续时间较对照组明显缩短(P<0.05),输注血小板量及次数较对照组减少(P<0.05)。实验组注射rhIL-11后不良反应均可耐受,不适症状在停药后逐渐消失。结论应用rhIL-11治疗急性髓系白血病化疗后血小板减少,不仅能明显提高化疗后患者的血小板数目,缩短血小板的恢复时间,而且不良反应轻微。

Therapeutic Effect and Evaluation of Recombinant Human Interleukin-11 on Chemotherapy-induced Thrombocytopenia in Patients with Acute Myeloid Leukemia

Objective To observe and evaluate the efficacy and adverse reactions of recombinant human interleukin-11 （rhIL-11） on chemotherapy-induced thrombocytopenia in patients with acute myeloid leukemia. Methods 45 acute myeloid leukemia patients with chemotherapy-induced thrombocytopenia were randomly divided into experimental group and control group. Cases in the experimental group received subcutaneous injection of rhIL-11 [30μg/（kg· d）] until the platelet count recovered to ≥ 50× 109/L, while those in the control group were not administered with rhIL-11. Results The mean platelet counts in the experimental group and control group before chemotherapy had no significant difference （P〉0.05）. The platelet count after chemotherapy in the experimental group was significantly higher than that in the control group （P〈0.05）. The time of platelet count increasing to 50×109/L in the experimental group was significantly shorter than that in the control group （P〈0.05）. The mean times and volume of platelet infusion in the experimental group after chemotherapy was decreased than that in the control group （P〈0.05）. The symptoms induced by the rhIL-11 was tolerable and disappeared when subcutaneous injection of rhIL-11 was stopped. Conclusion Administration of rhlL-11 in chemotherapy-induced thrombocytopenia patients with acute myeloid leukemia can not only enhance the platelet counts and shorten the recovery time of thrombocytopenia, but also has only mild adverse reactions.